JP2022531474A5 - - Google Patents

Info

Publication number
JP2022531474A5
JP2022531474A5 JP2021566008A JP2021566008A JP2022531474A5 JP 2022531474 A5 JP2022531474 A5 JP 2022531474A5 JP 2021566008 A JP2021566008 A JP 2021566008A JP 2021566008 A JP2021566008 A JP 2021566008A JP 2022531474 A5 JP2022531474 A5 JP 2022531474A5
Authority
JP
Japan
Application number
JP2021566008A
Other languages
Japanese (ja)
Other versions
JPWO2020227546A5 (https=
JP2022531474A (ja
JP7582971B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031898 external-priority patent/WO2020227546A1/en
Publication of JP2022531474A publication Critical patent/JP2022531474A/ja
Publication of JPWO2020227546A5 publication Critical patent/JPWO2020227546A5/ja
Publication of JP2022531474A5 publication Critical patent/JP2022531474A5/ja
Priority to JP2024011014A priority Critical patent/JP2024038503A/ja
Application granted granted Critical
Publication of JP7582971B2 publication Critical patent/JP7582971B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021566008A 2019-05-08 2020-05-07 T細胞製造組成物および方法 Active JP7582971B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024011014A JP2024038503A (ja) 2019-05-08 2024-01-29 T細胞製造組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962845251P 2019-05-08 2019-05-08
US62/845,251 2019-05-08
PCT/US2020/031898 WO2020227546A1 (en) 2019-05-08 2020-05-07 T cell manufacturing compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024011014A Division JP2024038503A (ja) 2019-05-08 2024-01-29 T細胞製造組成物および方法

Publications (4)

Publication Number Publication Date
JP2022531474A JP2022531474A (ja) 2022-07-06
JPWO2020227546A5 JPWO2020227546A5 (https=) 2023-05-16
JP2022531474A5 true JP2022531474A5 (https=) 2023-05-16
JP7582971B2 JP7582971B2 (ja) 2024-11-13

Family

ID=73051205

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021566008A Active JP7582971B2 (ja) 2019-05-08 2020-05-07 T細胞製造組成物および方法
JP2024011014A Pending JP2024038503A (ja) 2019-05-08 2024-01-29 T細胞製造組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024011014A Pending JP2024038503A (ja) 2019-05-08 2024-01-29 T細胞製造組成物および方法

Country Status (15)

Country Link
US (1) US20220280621A1 (https=)
EP (1) EP3965784A4 (https=)
JP (2) JP7582971B2 (https=)
KR (2) KR102756321B1 (https=)
CN (2) CN121086984A (https=)
AR (1) AR118859A1 (https=)
AU (1) AU2020268397A1 (https=)
BR (1) BR112021022363A2 (https=)
CA (1) CA3137037A1 (https=)
IL (1) IL287874A (https=)
MX (1) MX2021013608A (https=)
PH (1) PH12021552829A1 (https=)
SG (1) SG11202112346WA (https=)
TW (2) TWI777160B (https=)
WO (1) WO2020227546A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
CA3081840A1 (en) 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods
KR20210040355A (ko) * 2018-06-19 2021-04-13 바이오엔테크 유에스 인크. 네오항원 및 이의 용도
TWI777160B (zh) * 2019-05-08 2022-09-11 美商百歐恩泰美國公司 T細胞製備組合物及方法
EP4114400A4 (en) * 2020-03-05 2023-10-18 Exuma Biotech Corp. Methods and compositions for the delivery of modified lymphocyte aggregates
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
US20230374455A1 (en) * 2020-08-13 2023-11-23 Biontech Us Inc. T cell manufacturing compositions and methods
US11948694B2 (en) * 2021-05-12 2024-04-02 Merative Us L.P. Controlling compartmental flows in epidemiological modeling based on mobility data
US12062456B2 (en) 2021-05-27 2024-08-13 Merative Us L.P. Hypothetical scenario evaluation in infectious disease dynamics based on similar regions
IL312121A (en) * 2021-10-15 2024-06-01 Biontech Us Inc T cell manufacturing compositions and methods
WO2023159088A1 (en) * 2022-02-15 2023-08-24 Marker Therapeutics, Inc. Compositions and methods for antigen-specific t cell expansion
IL321246A (en) * 2022-12-09 2025-08-01 Biontech Us Inc Compositions and methods for producing T cells
WO2024151124A1 (ko) * 2023-01-12 2024-07-18 주식회사 이뮤노맥스 항암능이 우수한 기억 t 세포 유래 면역세포치료제의 제조방법
CN117417886B (zh) * 2023-10-20 2024-05-14 广东壹加再生医学研究院有限公司 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
WO2006110582A1 (en) * 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
DE102005046490A1 (de) * 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9809797B2 (en) * 2007-10-03 2017-11-07 National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
EP2749639B1 (en) * 2012-02-10 2016-10-12 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
RU2763795C2 (ru) * 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
DE102015214780A1 (de) * 2015-08-03 2017-02-09 Continental Automotive Gmbh Verfahren zur Erkennung fehlerhafter Komponenten eines Kraftstoffeinspritzsystems
AU2016306408B2 (en) * 2015-08-10 2021-02-11 Toray Industries, Inc. Immune inducer
EP3347051A4 (en) * 2015-09-10 2019-04-24 Affigen, Inc. SEQUENCING SELECTING TUMOR THEROSTICAS
WO2017059557A1 (en) * 2015-10-09 2017-04-13 Peking University Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use
AU2018337960B2 (en) * 2017-09-20 2025-08-14 Neximmune, Inc. Cell compositions comprising antigen-specific T cells for adoptive therapy
CA3081840A1 (en) * 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods
TWI777160B (zh) * 2019-05-08 2022-09-11 美商百歐恩泰美國公司 T細胞製備組合物及方法

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)